Spyre Therapeutics
SYRE
SYRE
92 hedge funds and large institutions have $319M invested in Spyre Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
92
Holders Change
-2
Holders Change %
-2.13%
% of All Funds
1.63%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
10
Increased
33
Reduced
29
Closed
12
Calls
$2K
Puts
$551K
Net Calls
-$549K
Net Calls Change
-$550K
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.9M |
| 3 |
Millennium Management
New York
|
+$3.19M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$1.81M |
| 5 |
BlackRock
New York
|
+$883K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
PCM
101
Prelude Capital Management
New York
| – | -$3K | -16 | Closed |
|
102
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3K | -15 | Closed |
|